Artelo Biosciences, Inc.
ARTL
$1.91
$0.2615.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.42M | 4.48M | 4.03M | 4.12M | 3.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.43M | 10.54M | 9.90M | 10.11M | 9.54M |
| Operating Income | -12.43M | -10.54M | -9.90M | -10.11M | -9.54M |
| Income Before Tax | -12.49M | -10.50M | -9.72M | -9.83M | -9.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.49 | -10.50 | -9.72 | -9.83 | -9.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.49M | -10.50M | -9.72M | -9.83M | -9.12M |
| EBIT | -12.43M | -10.54M | -9.90M | -10.11M | -9.54M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -22.77 | -20.91 | -19.82 | -20.19 | -18.83 |
| Normalized Basic EPS | -14.27 | -13.19 | -12.60 | -12.98 | -12.31 |
| EPS Diluted | -22.77 | -20.91 | -19.82 | -20.19 | -18.83 |
| Normalized Diluted EPS | -14.27 | -13.19 | -12.60 | -12.98 | -12.31 |
| Average Basic Shares Outstanding | 8.98M | 8.74M | 8.70M | 8.60M | 8.51M |
| Average Diluted Shares Outstanding | 8.98M | 8.74M | 8.70M | 8.60M | 8.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |